US3320262A - 14 hydroxy morphine and codeine carboxymethyloximes - Google Patents

14 hydroxy morphine and codeine carboxymethyloximes Download PDF

Info

Publication number
US3320262A
US3320262A US398426A US39842664A US3320262A US 3320262 A US3320262 A US 3320262A US 398426 A US398426 A US 398426A US 39842664 A US39842664 A US 39842664A US 3320262 A US3320262 A US 3320262A
Authority
US
United States
Prior art keywords
cyclopropylmethyl
hours
carboxymethyloxime
solution
codeine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US398426A
Inventor
Lewenstein Evalina
Fishman Jack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEWENSTEIN
Original Assignee
LEWENSTEIN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEWENSTEIN filed Critical LEWENSTEIN
Priority to US398426A priority Critical patent/US3320262A/en
Priority to GB37939/65A priority patent/GB1069969A/en
Application granted granted Critical
Publication of US3320262A publication Critical patent/US3320262A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:

Definitions

  • R is selected from the group consisting of methoxy and hydroxy, and R is selected from the group consisting of hydrogen and hydroxy, and wherein R is selected from the group consisting of H, CH CH CH CH3CH2CH2, and C6H5CH2.
  • the aforesaid compounds can be in combined form such as hydrochlorides, sulphates, and other acid salts; however when R is H, basic salts are utilizable.
  • compositions When used for pharmaceutical application, they can be combined with a pharmaceutically acceptable inert carrier of the type known in the art to be suitable for morphine and codeine derivatives, such as distilled Water, milksugar, starch, etc. and these resulting pharmaceutical compositions can be taken parenterally, orally or rectally.
  • a pharmaceutically acceptable inert carrier of the type known in the art to be suitable for morphine and codeine derivatives, such as distilled Water, milksugar, starch, etc.
  • Such compositions contain a major proportion of pharmaceutical carrier and a minor amount of compounds (I) or (La), the percentage of the active compound (I) or (I-a) generally falling within the range of 0.1 to of the total pharmaceutical composition.
  • Compounds of generic Formula I and I-a offer improved analgesic and antitussive effects. They may be employed for the relief of pain and cough in the same manner as morphine and codeine compounds in general. Evidence indicates that the present compounds may have low physical dependency and offer distinct advantages over morphine and codeine and their other derivatives.
  • compositions N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone- 6-carboxymethyloxime N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone- 6-carboxymethyloxime methylester N-cyclopropylmethyl-nor-dihydrocodeinone-6- carboxymethyloxime methylester N-cyclopropylmethyl-nor-14-hydroxydihydromorphinone-6-carboxymethyloxime methylester N-cyclopropylmethyl-nor-dihydromorphinone-6- carboxymethyloxime methylester
  • these compositions may well be methyl-esters, ethylesters, propyl-esters, allyl-esters, and benzyl-esters, as well as the free carboxymethyloximes.
  • R is selected from the group consisting of hydrogen and methyl and R" selected from the group consisting of hydrogen and hydroxyl.
  • a solvent such as absolute ethanol, N-propyl alcohol or dioxane may be employed as the solvent. Reaction times and temperatures are sufficient to cause reaction between the cyclopropylmethylhalide group and the nitrogen atom of II or II-a to form the resultant N-cyclopropylmethyl derivative. In general, temperatures of the order of 25 C. to 100 C., particularly 50 to are employed, with reaction period of /2 to 28 or more hours; the optimum time is a few hours.
  • bicarbonates, or other bases can be used as for example potassium carbonate, sodium carbonate, potassium bicarbonate and, generally, weak inorganic bases,
  • the resultant N-cyclopropylmethyl compounds may be recovered via any of the variety of conventional techniques, such as addition of water and extraction with a suitable organic solvent, such as chloroform, which may thereafter be evaporated toyield a N-cyclopropylmethylmorphine or codeine derivative.
  • a suitable organic solvent such as chloroform
  • the reaction mixture may be filtered and the solvent simply evaporated, to yield as a residue the desired intermediate product.
  • step (3) The resultant N-cyclopropylmethyl compound of step (1) is then reacted with the esterified carboxymethoxylamine of step (2) in aqueous dioxane containing sodium bicarbonate for 3 to 8 hours which is a sufficient time to produce the corresponding carboxymethyloxime ester derivatives of the N-cyclopropylmethyl compound.
  • methyl esters can be produced as follows:
  • step (1) The N-cyclopropylmethyl compound of step (1) is reacted with carboxymethoxylamine or its acid salts in an aqueous ethanol solvent additionally containing potassium or sodium hydroxide for a period of from 2 to 6 hours to produce the corresponding carboxymethyloxime derivative.
  • step (1) In general, about equal molar quantities of the product of step (1) are reacted with the carboxymethoxylamine or its acid salts. In general about 0.4 to 1.0 gram of carboxymethoxylamine or its acid salts are utilized per gram of intermediate, with the amount of base required being one equivalent of N-cyclopropylmethyl intermediate reacted. The amount of alcohol utilized is sufiicient to insure solution of the resultant product and control of the reaction temperature.
  • temperatures of the order of 50 C. to 95 C. can be utilized together with suitable reaction periods of 2 to 6 hours to form the corresponding carboxymethyloxime.
  • the product can be obtained by cooling to cause its crystallization, generally in combination with concentrating the reaction mixture after the reaction has been completed by the use of vacuum evaporation.
  • step (4) The resulting N-cyclopropylmethylcarboxymethyloxime-codeine or morphine derivative formed in step (4) is then further reacted with an excess of ethereal diazomethane to give methyl esters of the carboxymethyloximes.
  • reaction can take place by allowing the compounds to stand at room temperature in a suitable solvent such as ethanol.
  • a suitable solvent such as ethanol.
  • Room temperature conditions of under two hours, e.g. minutes to an hour, have been found to be suitable.
  • Reaction temperature may vary from 10 C. to 30 C. and the reaction period from 5 minutes upwards to 3 hours, preferably to minutes.
  • the resulting product may be recovered from the reaction medium by conventional techniques such as vacuum distillation or steam bath evaporation of the solvent, and recrystallization of the residue from a suitable solvent such as ethanol, chloroform, or the like.
  • Example 2 Carb0xymeth0xylamine benzylester 5 grams of carboxymethoxylaminesulfate is suspended in 75 cc. of benzyl alcohol and heated with stirring at 60 C. (under nitrogen) for 6 hours. The excess benzyl alcohol is then removed under vacuum on a steam bath, and the residue is partitioned between cc. of chloroform and 75 cc. of 5% aqueous sodium hydroxide. The chloroform layer is dried over sodium sulfate and evaporated to leave as the residue the benzylester of carboxymethoxylamine.
  • Example 3 --N-cyclopropylmethyl-nor-14 hydroxydihydr0m0rphinone-6-carboxymethyloxime benzylester
  • N-cyclopropylmethyl-nor-l4- hydroxydihydromorphinone 100 ml. of aqueous ethanol containing 0.5 g. sodium bicarbonate was added 3 grams of carboxymethoxylamine benzylester. The mixture was kept at 60 C. for 6 hours, and the solution was concentrated to /3 of the volume in vacuo and the product crystallized on cooling.
  • Example 5 -Carboxymethoxylamine allylester 5 grams of carboxymethoxylamine hydrochloride was suspended in 100 cc. of allyl alcohol and stirred under nitrogen at 40 C. for 10 hours. The alcohol was removed in vacuo at 30 C. and the residue was taken up in 100 cc. of methylene chloride and 75 cc. of 5% sodium hydroxide. The organic layer was dried and evaporated to leave the allyl ester of carboxymethoxylamine.
  • Example 6 N-cyclopropylmethyl-n0r-c0dein0ne-6- carboxymethyloxime allylester
  • N-cyclopropylmethyl-norcodeinone in 100 cc. of dioxane containing /2 g. of sodium bicarbonate was added 3.5 gr. of carboxymethoxylamine allylester.
  • the mixture was stirred at 50 C. for 8 hours and the solution concentrated to /3 of its volume in vacuo. On addition of 25 cc. of water and cooling the product crystallized.
  • Example 9.N-cyclopropylmethyl-n0r-14-hydr0xyc0deinone-6-carb0xymethyloxime propylester To a solution of 6 gr. of carboxylmethoxylamine propylester hydrochloride in 50 cc. of one normal potassium hydroxide was added a solution of 8 g. of N-cyclopropylmethyl-nor-14-hydroxycodeinone and 150 ml. of ethanol. The mixture was heated at 65 C. for 10 hours and then concentrated to A of the volume in vacuo. 50 cc. of water were then added and on cooling the product crystallized.
  • Example 11 Carb0xymetlz0xylamine etlzylester 10 grams of carboxymethylamine hydrochloride is dissolved in 75 cc. of ethyl alcohol and heated at reflux for 9 hours. The ethyl alcohol is removed in vacuo and the residue is treated with cold l-normal sodium solution hydroxide and the resultant suspension extracted with 100 cc. of chloroform. The chloroform is dried and evaporated to give the desired product.
  • Example 12 -N-cycl0pr0pylmethyl-no-r-dihydromorphinone-6-carboxymethyl0xime ethylester
  • N-cycloproylmethyl-nordihydromorphinone in 100 ml. of ethanol containing 1 gram of sodium bicarbonate is added 3 /2 grams of carboxymethoxylamine ethyl ester.
  • the solution is stirred under nitrogen at 60 C. for 15 hours. his then concentrated to A of the volume and 20 cc. of water is added. The product crystallizes on cooling.
  • the chloroform was then extracted with 2x100 ml. of dilute hydrochloric acid.
  • the acid solution was treated with charcoal, filtered and made to pH 9.5 with concentrated ammonia.
  • the basic solution was then extracted with 3x100 cc. chloroform and the chloroform was dried over Na SO and evaporated. The residue was recrystallized from ethanol to give the product.
  • Example 15 -N cyclopropylmethyl nor 14 hydroxyaihydroc0dein0ne-6-carb0xymethyloxime methyl ester
  • a solution of N-cyclopropylmethyl-nor-l4-hydroxydihydrocodeinone-6-carboxymethyloxime in ethanol was treated with an ethereal diazomethane solution until the yellow color persisted. After standing at room temperature for 1 hour, the solvents were removed by evaporation on a steam bath and the residue was recrystallized from ethanol to give the product.
  • N-cyclopropylmethyl-nor 14 hydroxydihydrocodeinone 6 carboxymethyloxime methylester was found to have al-agesic effect when tested by the hotplate method equivalent to and E13 of 16.2 mg. per kg. bodyweight in mice subcutaneously.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

codeine derivatives.
United States Patent 3,320,262 14 HYDROXY MORPHINE AND CODEINE CARBOXYMETHYLOXIMES Mozes J. Lewenstein, 80-49 Park Lane, Kew Gardens, N.Y. 11415; Evalina Lewenstein, executrix of Moles J. Lewenstein, deceased, and Jack Fishman, New York, N.Y.; said Fishman assignor to said Lewenstein No Drawing. Filed Sept. 22, 1964, Ser. No. 398,426 12 Claims. (Cl. 260-2S5) (I) OH:
wherein R is selected from the group consisting of methoxy and hydroxy, and R is selected from the group consisting of hydrogen and hydroxy, and wherein R is selected from the group consisting of H, CH CH CH CH3CH2CH2, and C6H5CH2.
The aforesaid compounds can be in combined form such as hydrochlorides, sulphates, and other acid salts; however when R is H, basic salts are utilizable.
When used for pharmaceutical application, they can be combined with a pharmaceutically acceptable inert carrier of the type known in the art to be suitable for morphine and codeine derivatives, such as distilled Water, milksugar, starch, etc. and these resulting pharmaceutical compositions can be taken parenterally, orally or rectally. Such compositions contain a major proportion of pharmaceutical carrier and a minor amount of compounds (I) or (La), the percentage of the active compound (I) or (I-a) generally falling within the range of 0.1 to of the total pharmaceutical composition.
Compounds of generic Formula I and I-a offer improved analgesic and antitussive effects. They may be employed for the relief of pain and cough in the same manner as morphine and codeine compounds in general. Evidence indicates that the present compounds may have low physical dependency and offer distinct advantages over morphine and codeine and their other derivatives.
The following are specific examples of the compounds of Formula I:
N-cyclopropylmethyl-nor-14-hydroxycodeinone-6- carboxymethyloxime N-cyclopropylmethyl-nor-codeinone-6-carboxymethyloxime 3,320,262 Patented May 16, 1967 N-cyclopropylmethyl-nor-14-hydroxymorphinone-6- carboxymethyloxime N-cyclopropylmethyl-nor-morphinone-G-carboxymethyloxime methylester The following are specific examples of the compounus of Formula I-a:
N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone- 6-carboxymethyloxime N-cyclopropylmethyl-nor-14-hydroxydihydrocodeinone- 6-carboxymethyloxime methylester N-cyclopropylmethyl-nor-dihydrocodeinone-6- carboxymethyloxime methylester N-cyclopropylmethyl-nor-14-hydroxydihydromorphinone-6-carboxymethyloxime methylester N-cyclopropylmethyl-nor-dihydromorphinone-6- carboxymethyloxime methylester Although we have illustrated some compositions as being carboxymethyloximes and some as their methylesters, these compositions may well be methyl-esters, ethylesters, propyl-esters, allyl-esters, and benzyl-esters, as well as the free carboxymethyloximes.
The carboxymethyloximes of the 6 ketone derivatives of morphine and codeine and their esters as set forth in generic Formulae I and Ia are prepared by a series of reaction stages as follows:
wherein R is selected from the group consisting of hydrogen and methyl and R" selected from the group consisting of hydrogen and hydroxyl.
(l) A compound having the structure II or II-a is reacted with cyclopropylmethylhalide and sodium bicarbonate in an appropriate solvent to produce the resultant N- cyclopropylmethyl compound.
In such initial reaction stage a solvent such as absolute ethanol, N-propyl alcohol or dioxane may be employed as the solvent. Reaction times and temperatures are sufficient to cause reaction between the cyclopropylmethylhalide group and the nitrogen atom of II or II-a to form the resultant N-cyclopropylmethyl derivative. In general, temperatures of the order of 25 C. to 100 C., particularly 50 to are employed, with reaction period of /2 to 28 or more hours; the optimum time is a few hours.
Other bicarbonates, or other bases can be used as for example potassium carbonate, sodium carbonate, potassium bicarbonate and, generally, weak inorganic bases,
The resultant N-cyclopropylmethyl compounds may be recovered via any of the variety of conventional techniques, such as addition of water and extraction with a suitable organic solvent, such as chloroform, which may thereafter be evaporated toyield a N-cyclopropylmethylmorphine or codeine derivative. Alternately, the reaction mixture may be filtered and the solvent simply evaporated, to yield as a residue the desired intermediate product.
(2) The acid salt of carboxymethoxylamine is dissolved in the appropriate alcohol and heated for 1 to 24 hours at a temperature of 50 to 100 C., depending upon the alcohol used, to yield the desired ester of the carboxymethoxylamine. The products are obtained by removing the excess alcohol under vacuum and partitioning the residue between chloroform and dilute sodium hydroxide solution. The chloroform is then dried and evaporated to leave the desired product as the residue. This may then be converted to the acid salt by treatment with the appropriate acid.
(3) The resultant N-cyclopropylmethyl compound of step (1) is then reacted with the esterified carboxymethoxylamine of step (2) in aqueous dioxane containing sodium bicarbonate for 3 to 8 hours which is a sufficient time to produce the corresponding carboxymethyloxime ester derivatives of the N-cyclopropylmethyl compound.
Alternatively, the methyl esters can be produced as follows:
(4) The N-cyclopropylmethyl compound of step (1) is reacted with carboxymethoxylamine or its acid salts in an aqueous ethanol solvent additionally containing potassium or sodium hydroxide for a period of from 2 to 6 hours to produce the corresponding carboxymethyloxime derivative.
In general, about equal molar quantities of the product of step (1) are reacted with the carboxymethoxylamine or its acid salts. In general about 0.4 to 1.0 gram of carboxymethoxylamine or its acid salts are utilized per gram of intermediate, with the amount of base required being one equivalent of N-cyclopropylmethyl intermediate reacted. The amount of alcohol utilized is sufiicient to insure solution of the resultant product and control of the reaction temperature.
In general temperatures of the order of 50 C. to 95 C. can be utilized together with suitable reaction periods of 2 to 6 hours to form the corresponding carboxymethyloxime. The product can be obtained by cooling to cause its crystallization, generally in combination with concentrating the reaction mixture after the reaction has been completed by the use of vacuum evaporation.
(5) The resulting N-cyclopropylmethylcarboxymethyloxime-codeine or morphine derivative formed in step (4) is then further reacted with an excess of ethereal diazomethane to give methyl esters of the carboxymethyloximes.
This reaction can take place by allowing the compounds to stand at room temperature in a suitable solvent such as ethanol. Room temperature conditions of under two hours, e.g. minutes to an hour, have been found to be suitable. Reaction temperature may vary from 10 C. to 30 C. and the reaction period from 5 minutes upwards to 3 hours, preferably to minutes.
However, the resulting product may be recovered from the reaction medium by conventional techniques such as vacuum distillation or steam bath evaporation of the solvent, and recrystallization of the residue from a suitable solvent such as ethanol, chloroform, or the like.
The various aspects and modifications of the present invention will be made more clearly apparent by reference to the following description and accompanying examples. In these examples each series of reactions used in forming the esters of carboxymethyloximes of the 6-ket0ne derivatives of N-cyclopropylmethyl-nor-morphine and N- cyclopropylmethyl-nor-codeine, aredesignated by Roman letters.
The above is a preferred procedure forthe preparation of the carboxymethyloximes a'ndtheir esters, however, modifications in this procedure such as time, temperature and solvents may be adopted for the production of the said carboxymethyloximes and their esters.
There are listed below five examples of appropriate series of reactions utilizable in producing the compositions of the various groupings additionally delineated.
(I) N CYCLOPROPYLMETHYL NOR 1 4 HY- DROXYDIHYDROMORPHINONE 6 CARBOXY- METHYLOXIME BENZYLESTER Example 1.N-cycl0pr0pylmethyl-nor-I4 hydroxydi= hydromorphinone 5 grams N-nor-l4-hydroxydihydromorphinone was dissolved in 200 cc. of absolute ethanol, and 3 grams of sodium bicarbonate was added, after which 3 g. of cyclopropylmethylbromide were added dropwise with stirring. After the addition was complete the mixture was heated at 60 C. for 14 hours. Filtration was followed by evaporation of solvent and the residue was recrystallized from ethanol to give the product.
Example 2.Carb0xymeth0xylamine benzylester 5 grams of carboxymethoxylaminesulfate is suspended in 75 cc. of benzyl alcohol and heated with stirring at 60 C. (under nitrogen) for 6 hours. The excess benzyl alcohol is then removed under vacuum on a steam bath, and the residue is partitioned between cc. of chloroform and 75 cc. of 5% aqueous sodium hydroxide. The chloroform layer is dried over sodium sulfate and evaporated to leave as the residue the benzylester of carboxymethoxylamine.
Example 3.--N-cyclopropylmethyl-nor-14 hydroxydihydr0m0rphinone-6-carboxymethyloxime benzylester To a solution of 5 g. of N-cyclopropylmethyl-nor-l4- hydroxydihydromorphinone in 100 ml. of aqueous ethanol containing 0.5 g. sodium bicarbonate was added 3 grams of carboxymethoxylamine benzylester. The mixture was kept at 60 C. for 6 hours, and the solution was concentrated to /3 of the volume in vacuo and the product crystallized on cooling.
(II) N CYCLOPROPYLMETHYL NOR CODEI- NONE 6 CARBOXYMETHYLOXIME ALLYL- ESTER Example 4.-N-cyclopropylmethyl-nor-codeinone To a solution of 6 g. of nor-codeinone in 66 cc. of propyl alochol was added 3 grams of cyclopropylmethyl chloride and 3 grams of sodium bicarbonate, the resulting suspension was heated at 60 C. for 6 hours. The solvent was removed under reduced pressure and the residue taken up in 100 ml. of chloroform. The chloroform layer was washed with water and extracted with 100 ml. of dilute sulfuric acid. The acid solution was made to pH 10 with sodium carbonate and then extracted with three times 75 cc. of chloroform. The chloroform was dried over sodium sulfate and evaporated. The residue represented the desired product.
Example 5 .-Carboxymethoxylamine allylester 5 grams of carboxymethoxylamine hydrochloride was suspended in 100 cc. of allyl alcohol and stirred under nitrogen at 40 C. for 10 hours. The alcohol was removed in vacuo at 30 C. and the residue was taken up in 100 cc. of methylene chloride and 75 cc. of 5% sodium hydroxide. The organic layer was dried and evaporated to leave the allyl ester of carboxymethoxylamine.
Example 6 .N-cyclopropylmethyl-n0r-c0dein0ne-6- carboxymethyloxime allylester To a solution of 5 grams of N-cyclopropylmethyl-norcodeinone in 100 cc. of dioxane containing /2 g. of sodium bicarbonate was added 3.5 gr. of carboxymethoxylamine allylester. The mixture was stirred at 50 C. for 8 hours and the solution concentrated to /3 of its volume in vacuo. On addition of 25 cc. of water and cooling the product crystallized.
(III) N CYCLOPROPYLMETHYL NOR 14 HY DROXYCODEINONE 6 CARBOXYMETHYL- OXIME PROPYLESTER Example 7.N-cycl0propylmethyl-nor- 14-hydr0xyc0dein0ne A gram sample of nor-l4-hydroxycodeinone was dissolved in 100 ml. of dioxane and 6 g. of sodium bicarbonate was added. To the stirred suspension a solution of 6 g. cyclopropylmethylbromide in 50 ml. of dioxane was added dropwise. The mixture was then stirred and heated at 75 C. for 16 hours. It was then filtered and the dioxane was removed in vacuo. The residue crystallized from ethylacetate to yield the product.
Example 8.Carboxymeth0xylamine propylester hydrochloride Example 9.N-cyclopropylmethyl-n0r-14-hydr0xyc0deinone-6-carb0xymethyloxime propylester To a solution of 6 gr. of carboxylmethoxylamine propylester hydrochloride in 50 cc. of one normal potassium hydroxide was added a solution of 8 g. of N-cyclopropylmethyl-nor-14-hydroxycodeinone and 150 ml. of ethanol. The mixture was heated at 65 C. for 10 hours and then concentrated to A of the volume in vacuo. 50 cc. of water were then added and on cooling the product crystallized.
(IV) N CYCLOPROPYLMETHYL NOR DIHY- DROMGRPHINONE 6 CARBOXYMETHYLOX- IME ETHYLESTER Example 10.N-cycl0pr0pylmethyl-nor-a'ihydromorphino ne A 10 gram sample of nor-dihydromorphinone was dissolved in 100 ml. of n-propyl alcohol and 6 g. sodium bicarbonate was added. To the stirred suspension a solution of 6 g. cyclopropylmethyl bromide in 50 ml. of n-propyl alcohol was added dropwise. The mixture was then stirred and heated at 75 C. for 16 hours. It was then filtered and the n-propanol was removed in vacuo. The residue crystallized from ethyl-acetate to yield the product.
Example 11.Carb0xymetlz0xylamine etlzylester 10 grams of carboxymethylamine hydrochloride is dissolved in 75 cc. of ethyl alcohol and heated at reflux for 9 hours. The ethyl alcohol is removed in vacuo and the residue is treated with cold l-normal sodium solution hydroxide and the resultant suspension extracted with 100 cc. of chloroform. The chloroform is dried and evaporated to give the desired product.
Example 12.-N-cycl0pr0pylmethyl-no-r-dihydromorphinone-6-carboxymethyl0xime ethylester To a solution of 6 grams of N-cycloproylmethyl-nordihydromorphinone in 100 ml. of ethanol containing 1 gram of sodium bicarbonate is added 3 /2 grams of carboxymethoxylamine ethyl ester. The solution is stirred under nitrogen at 60 C. for 15 hours. his then concentrated to A of the volume and 20 cc. of water is added. The product crystallizes on cooling.
(V) N CYCLOPROPYLMETHYL NOR l4 HY- DROXYDIHYDROCODEINONE 6 CARBOXY- METHYLOXIME METHYL ESTER Example 1 3 N -cycl0 pro pylmethyl-nor-l 4-hydr0xydihydrocodeinone To a solution of 1 0 grams of nor-l4-hydroxydihydrocodeinone in 150 cc. absolute ethanol was added 5 grams of cyclopropylmethylbromide and 5 grams of sodium bicarbonate. The resulting suspension was refluxed for 48 hours. The solvent was removed under reduced pressure and the residue was taken up in 200 ml. chloroform, which was washed with water. The chloroform was then extracted with 2x100 ml. of dilute hydrochloric acid. The acid solution was treated with charcoal, filtered and made to pH 9.5 with concentrated ammonia. The basic solution was then extracted with 3x100 cc. chloroform and the chloroform was dried over Na SO and evaporated. The residue was recrystallized from ethanol to give the product.
Example 14.N-cycl0pr0py lm ethy l-nor-J 4-hydr0xydihydrocodein0ne-6-carb0xymethyl0xime To a solution of 10 grams of N-cyclopropylmethyl-norl4-hydroxydihydrocodeinone in ml. of ethanol was added 8 grams of carboxymethoxylamine hydrochloride and 35 ml. of 2 N KOH solution. The mixture was refiuxed at 72 C. for 8 hours and the volume was concentrated to /3 under reduced pressure. The product crystallized on cooling, and could be recrystallized from dilute ethanol.
Example 15.-N cyclopropylmethyl nor 14 hydroxyaihydroc0dein0ne-6-carb0xymethyloxime methyl ester A solution of N-cyclopropylmethyl-nor-l4-hydroxydihydrocodeinone-6-carboxymethyloxime in ethanol was treated with an ethereal diazomethane solution until the yellow color persisted. After standing at room temperature for 1 hour, the solvents were removed by evaporation on a steam bath and the residue was recrystallized from ethanol to give the product.
A representative compound of the present invention,
namely, N-cyclopropylmethyl-nor 14 hydroxydihydrocodeinone 6 carboxymethyloxime methylester was found to have al-agesic effect when tested by the hotplate method equivalent to and E13 of 16.2 mg. per kg. bodyweight in mice subcutaneously.
It was employed also in a series of tests with monkeys to determine its physical dependency characteristics and duration of drug action. These tests were performed in the following manner:
Monkeys, physically dependent on 3 mg./kg. morphine sulfate g6h, were withdrawn until abstinence signs of intermediate severity were present (12 to 14 hours). N-cyclopropylmethyl nor 14 hydroxydihydrocodeinone 6 carboxymethyloxime methyester was injected at this time in the dosage units indicated below; the monkeys were graded just prior to injection and at intervals of /2, 1, 2, 3, 4, 5, and 6 hours after injection. Grades were based on withdrawal intensity of opiatelike depression and side effects.
It was found that at dosages of 1 and 2 mg./kg. of body weight, partial suppression of symptoms was obtained. The duration of action was about 4 hours and the physical dependency of the drug was indicated to be low.
Various modifications may be made to and Within the present invention.
Having described the present invention, that which is sought to be protected is set forth in the following claims.
7 What is claimed is: 1. Carhoxymethyloxime compound of the formula:
(ilHr-CHCHI N wherein R is selected from the group consisting of hydroxy and methoxy, and R is selected from the group consisting of hydrogen or hydroxy, and wherein R is selected from the group consisting of H, CH CH CH CH CH CH CH=CH-CH and C H CH 7. N-cyclopropylmethyl nor 14 hydroxydihydrocodeinone-6-carboxymethyloxime.
8. N-cyclopropylmethyl nor dihydrocodeinone-6- carboxymethyloxime methylester.
9. N-cyclopropylmethyl nor 14 hydroxydihydroc0deinone-6-carboxymethyloxime methylester.
10. N-cyclopropylmethyl nor 14 hydroxydihydromorphinone-6-carboxymethyloxime methylester.
11. The ca-rboxymethyloxime compounds of claim 1 wherein R is hydrogen.
12. The carboxyrnethyloxime compounds of claim 6 wherein R is hydrogen.
References Cited by the Examiner UNITED STATES PATENTS 2,770,569 11/1956 From'herz 16765 3,060,091 10/ 1962 Witkin 167-65 3,080,287 3/1963 Lewenstein 167-65 3,135,758 6/1964 Fishman 260-285 3,162,639 12/1964 Fishman 260-285 OTHER REFERENCES Braun et al.: Ber. Dcut. Chem., vol. 59, pp. 1081-1090 (1926).
Gates and Montzka: J. Med. Chem., v01. 7, pp. 127-31 (1964).
Montzka: Dissert. Ahst., col. 23, p. 3124 (1963).
ALEX MAZEL, Primary Examiner. HENRY R. JILES, NICHOLAS S. RIZZO, Examiners.
DONALD G. DAUS, Assistant Examiner.

Claims (1)

1. CARBOXYMETHYLOXIME COMPOUND OF THE FORMULA:
US398426A 1964-09-22 1964-09-22 14 hydroxy morphine and codeine carboxymethyloximes Expired - Lifetime US3320262A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US398426A US3320262A (en) 1964-09-22 1964-09-22 14 hydroxy morphine and codeine carboxymethyloximes
GB37939/65A GB1069969A (en) 1964-09-22 1965-09-06 Morphine and codeine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US398426A US3320262A (en) 1964-09-22 1964-09-22 14 hydroxy morphine and codeine carboxymethyloximes

Publications (1)

Publication Number Publication Date
US3320262A true US3320262A (en) 1967-05-16

Family

ID=23575336

Family Applications (1)

Application Number Title Priority Date Filing Date
US398426A Expired - Lifetime US3320262A (en) 1964-09-22 1964-09-22 14 hydroxy morphine and codeine carboxymethyloximes

Country Status (2)

Country Link
US (1) US3320262A (en)
GB (1) GB1069969A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393197A (en) * 1966-01-19 1968-07-16 Endo Lab Nu-substituted-14-hydroxydihydronormorphines
US4141897A (en) * 1976-12-20 1979-02-27 Research Corporation N-dealkylation of N-alkyl-14-hydroxymorphinans and derivatives thereof
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
WO1987001703A1 (en) * 1985-09-23 1987-03-26 Janusz Waclaw Rzeszotarski Potent, selective opioid receptor agonists and antagonists
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
JP2007526217A (en) * 2003-06-04 2007-09-13 アルカーメス，インコーポレイテッド Polymorphic form of naltrexone

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2770569A (en) * 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3060091A (en) * 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3080287A (en) * 1957-08-05 1963-03-05 Lewenstein Mozes Juda Analgesic compositions
US3135758A (en) * 1961-05-17 1964-06-02 Mozes Juda Lewenstein Morphinone and codeinone derivatives
US3162639A (en) * 1964-12-22 G-desoxy-ix-hydroxy-dihydromorphine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3162639A (en) * 1964-12-22 G-desoxy-ix-hydroxy-dihydromorphine
US2770569A (en) * 1952-08-01 1956-11-13 Hoffmann La Roche Analgesic compositions
US3080287A (en) * 1957-08-05 1963-03-05 Lewenstein Mozes Juda Analgesic compositions
US3060091A (en) * 1961-02-13 1962-10-23 Ciba Geigy Corp Analgesic composition consisting of morphines and amino-indanes
US3135758A (en) * 1961-05-17 1964-06-02 Mozes Juda Lewenstein Morphinone and codeinone derivatives

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393197A (en) * 1966-01-19 1968-07-16 Endo Lab Nu-substituted-14-hydroxydihydronormorphines
US4141897A (en) * 1976-12-20 1979-02-27 Research Corporation N-dealkylation of N-alkyl-14-hydroxymorphinans and derivatives thereof
US4161597A (en) * 1976-12-20 1979-07-17 Research Corporation N-alkyl-14-hydroxymorphinans and derivatives
WO1983003197A1 (en) 1982-03-16 1983-09-29 Univ Rockefeller Method for controlling gastrointestinal dysmotility
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
WO1987001703A1 (en) * 1985-09-23 1987-03-26 Janusz Waclaw Rzeszotarski Potent, selective opioid receptor agonists and antagonists
US4760069A (en) * 1985-09-23 1988-07-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4889860A (en) * 1985-09-23 1989-12-26 Nova Pharmaceutical Corporation Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists
US4730048A (en) * 1985-12-12 1988-03-08 Regents Of The University Of Minnesota Gut-selective opiates
US4806556A (en) * 1985-12-12 1989-02-21 Regents Of The University Of Minnesota Gut-selective opiates
JP2007526217A (en) * 2003-06-04 2007-09-13 アルカーメス，インコーポレイテッド Polymorphic form of naltrexone
US8389540B2 (en) 2003-06-04 2013-03-05 Alkermes, Inc. Polymorphic forms of naltrexone

Also Published As

Publication number Publication date
GB1069969A (en) 1967-05-24

Similar Documents

Publication Publication Date Title
US4272541A (en) 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US3814768A (en) 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US3320262A (en) 14 hydroxy morphine and codeine carboxymethyloximes
US2838519A (en) Process for the conversion of stereoisomers
US3773940A (en) 1,2,3,8-tetrahydrodibenzo(3,4:6,7)cyclohepta(1,2-c)pyrroles as cns-depressants
US3896226A (en) 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts thereof, and use of the same as a narcotic antagonist
US3318886A (en) Substituted 7-hydroxymethyl-7, 8-dihydro-6-amino-6, 14-endoethenocodides and morphide
US2824874A (en) Reserpic acid and derivatives
US3420834A (en) 2,3-dimethoxy-berbines substituted in the 10 position and process
CH617699A5 (en)
US3666762A (en) 2{40 {62 -ISOPROPYL-5{40 {60 -n-PROPYL-9,10-DIHYDRO-ERGOPEPTINES
US3372165A (en) 1, 2, 3, 4, 5, 6-hexahydro-8-hydroxy-2, 6-methano-3-benzazocine derivatives
US3658802A (en) Cephalosporine derivatives and process
US2474796A (en) Alkylaminoalkyl esters of alicyclyl-alicyclic carboxylic acids
US3542787A (en) 10,11-dihydro-5,10-(iminomethano)-5h-dibenzo(a,d)cyclohepten-13-imine
US3766188A (en) Carbonyldioxymorphinan derivatives
US3673189A (en) Tetracyclic isoquinoline derivatives
US5204355A (en) 15-nitro-2β, 3β-dihydro- and 15-nitro-2β,3β,6,7-tetrahydrotabersonine derivatives, pharmaceutical compositions containing them and process for preparing same
US3498992A (en) Substituted 1,2,3,6-tetrahydro-4-pyridine acetic acid amides
US3950346A (en) Novel process for producing 2-ketoethylbenzomorphan derivatives and salts thereof
US3359161A (en) Thiaxanthenols, process of producing and anti-tussive compositions thereof
US3966939A (en) Novel 2-substituted 6,7-benzomorphan derivatives and salts thereof in analgesic compositions
US3961066A (en) 6,7-Benzomorphan derivatives
US3317544A (en) 3-tropinyl esters of substituted acrylic and thio acrylic acids
US4021560A (en) 2-[(Dimethylamino)(3-pyridyl)methyl]cyclohexanol and related compounds